US2018125867A1PendingUtilityA1
Compositions for treating neurological disorders
Est. expiryMar 1, 2031(~4.6 yrs left)· nominal 20-yr term from priority
A61P 25/02A61P 25/28A61P 25/00A61K 31/138A61K 45/06A61K 31/496A61K 31/445A61K 31/64A61K 31/4709A61K 2300/00A61K 31/42A61K 31/423A61K 31/48A61K 31/185A61K 31/495A61K 31/155A61K 31/50A61K 31/167A61K 31/28A61K 31/137A61K 31/197A61K 31/4985A61K 31/44A61K 31/4164A61K 31/585
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A method for treating a neurological disorder selected from Alzheimer's disease, an Alzheimer's related disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, in a subject in need thereof, comprising administering to said subject (i) torasemide, or a salt or sustained release formulation thereof, in combination with (ii) at least one further compound selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplerenone, fenoldopam, leflunomide, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, or bromocriptine, or salt(s) or sustained release formulation(s) thereof.
2 . The method of claim 1 , comprising administering at least one of the following combinations of compounds:
sulfisoxazole and torasemide, eplerenone and torasemide, terbinafine and torasemide, sulfisoxazole and trimetazidine and torasemide and zonisamide, or sulfisoxazole and mexiletine and torasemide and cinacalcet, or salts or sustained release formulations thereof.
3 . The method of claim 1 , wherein the compounds in said combination are formulated with a pharmaceutically acceptable carrier or excipient.
4 . The method of claim 1 , wherein the compounds in said combination are formulated or administered together, separately or sequentially.
5 . The method of claim 1 , wherein the compounds are administered repeatedly to the subject.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.